PROCEPT Biorobotics Corp (PRCT) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. PROCEPT Biorobotics Corporation develops and sells the AquaBeam and HYDROS robotic systems for the treatment of benign prostatic hyperplasia (BPH) using Aquablation therapy. As of March 31, 2025, the company reported a global install base of 703 robotic systems, including 547 in the United States. The company received FDA 510(k) clearance for its next-generation HYDROS Robotic System in August 2024.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $69.2 million | $44.5 million |
| Gross Profit | $44.2 million | $25.0 million |
| Gross Margin | 64% | 56% |
| Net Loss | $(24.7) million | $(26.0) million |
| Net Loss Per Share (Basic/Diluted) | $(0.45) | $(0.51) |
| Cash and Cash Equivalents | $316.2 million | $225.6 million |
| Long-Term Debt | $51.5 million | $51.5 million |
| Operating Cash Flow | $(17.0) million | $(32.3) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 55% year-over-year, driven by a $20.1 million increase in U.S. revenue. This was attributed to higher sales volumes of systems, handpieces, consumables, and service contracts.
- Margin Expansion: Gross margin improved from 56% to 64%, primarily due to increased unit sales allowing for better absorption of fixed manufacturing overhead costs and higher average selling prices.
- Expense Increases: Operating expenses rose 36% to $71.6 million. Selling, General, and Administrative (SG&A) expenses increased 39% due to commercial organization expansion, while R&D expenses increased 25% due to product development and stock-based compensation.
- Debt Status: The company achieved the $200 million trailing twelve-month revenue target as of December 31, 2024, extending the interest-only period on its $52.0 million term loan facility. A $2.0 million loan facility liability became due and is recorded as a current liability.
Guidance, Outlook, and Risks
Outlook: Management expects expenses to increase in the foreseeable future to support sales, marketing, and R&D investments. The company believes its existing cash and anticipated revenue are sufficient to fund operations for at least the next twelve months. Strategic focus remains on growing the install base and increasing system utilization to drive recurring revenue from consumables.
Risks and Contingencies:
- Trade Policy: New U.S. tariffs enacted since February 2025 on imports, including components sourced from China (e.g., ultrasound systems), pose a risk to gross margins and supply chain stability.
- Reimbursement: Continued reliance on third-party payors (Medicare and commercial insurers) for coverage decisions is critical for market adoption.
- Legal: No material legal proceedings are currently pending that would have a material adverse effect.
Investor Verification Checklist
- Verify the sustainability of the 64% gross margin as the company scales production volumes.
- Monitor the impact of new U.S. tariffs on the cost of imported components and overall gross margin.
- Track the growth of the install base (currently 703 systems) and the resulting utilization rates for consumable handpieces.
- Review the timeline for amortization payments on the $52.0 million term loan, which begins after the extended interest-only period.
- Assess the effectiveness of commercial expansion efforts in driving U.S. revenue growth, which accounted for 87% of total revenue.